Читать книгу Clinical Pharmacology and Therapeutics - Группа авторов - Страница 132

The new drug compound for neuroprotection has now been tested in Phase III clinical trials and has shown good efficacy with an acceptable side‐effect profile. It gets approved by the regulatory authorities and the company wants to start marketing the drug. Is there a limit to what the company can do in its marketing strategy? How is its safety monitored? What happens if concerns about side effects become apparent?